Versatile Viral Vector Strategies for Postscreening Target Validation and RNAi ON-Target Control

Area of Science:

• Molecular Biology
• Gene Silencing Technologies
• Preclinical Drug Development

Background:

• High-throughput RNA interference (RNAi) screens identify numerous potential drug targets.
• Validating these targets effectively is crucial but challenging, often leading to costly errors.
• Existing validation methods may have limitations in efficiency and potential off-target effects.

Purpose of the Study:

• To develop and validate an optimized platform for postscreening target validation.
• To enhance the predictability and reliability of RNAi screening outcomes.
• To provide a reversible system for on-target phenotype verification, minimizing off-target effects.

Main Methods:

• Development of the RNAiONE validation platform using plasmid-based expression vectors for tandem gene of interest (GOI) and small hairpin RNA (shRNA) expression.
• Utilizing lentiviral vectors for inducible, homogeneous transduction of relevant cell types.
• Integration of VariCHECK for inducible knockdown and GOI rescue for phenotype verification.

Main Results:

• The RNAiONE-VariCHECK system achieves high predictability through focused shRNA validation (>85% silencing efficiency).
• Sophisticated viral vector technologies ensure homogeneity of RNAi cell pools.
• Inducible expression systems allow for reversible gene silencing and rescue, enabling robust on-target verification.

Conclusions:

• The RNAiONE-VariCHECK system offers a credible and efficient method for validating RNAi screening hits.
• This approach mitigates risks associated with irreversible genomic manipulation techniques.
• It provides critical information for early-stage preclinical drug development, reducing misinterpretations and costs.